Hormonal Therapy and Chemoprevention

Area of Science:

• Oncology
• Endocrinology
• Pharmacology

Background:

• Hormone replacement therapy (HRT) improves quality and length of life but increases breast cancer risk.
• Selective estrogen receptor modulators (SERMs) like tamoxifen can mitigate risks associated with HRT.
• Tamoxifen's endometrial effects are dose and time-dependent, suggesting dose reduction may lower cancer risk.

Purpose of the Study:

• To evaluate the potential benefits and risks of combining HRT with tamoxifen for breast cancer prevention.
• To explore the efficacy of reduced tamoxifen dosages in conjunction with HRT.
• To assess the impact of this combination on endometrial cancer risk and patient compliance.

Main Methods:

• Post hoc analysis of the Italian Tamoxifen Prevention Study data.
• Review of findings from the National Surgical Adjuvant Breast Project (NSABP) P-1 trial.
• Examination of dose-dependent effects of tamoxifen and HRT interactions.

Main Results:

• A borderline significant reduction in breast cancer was observed with continuous HRT and tamoxifen versus HRT and placebo.
• Reduced tamoxifen dosage (10 mg every other day) may maintain biological efficacy.
• HRT with progestins may reduce endometrial cancer risk associated with tamoxifen.
• Estrogen in HRT can alleviate vasomotor and urogenital symptoms, improving tamoxifen adherence.
• Younger women (≤50) in the NSABP P-1 trial showed no increased adverse events, possibly due to adequate estrogen levels.

Conclusions:

• Combining HRT with low-dose tamoxifen shows promise for breast cancer prevention.
• This combination may reduce risks and side effects while retaining therapeutic benefits.
• Improved compliance and reduced endometrial cancer risk are potential advantages of this combined therapy.